Endothelin-1 (ET-1) contributes to age-related endothelial dysfunction in men via the ETA 22 receptor. However, there are sex differences in the ET-1 system, and ETB receptors are 23 modulated by sex hormones. The purpose of this study was to test the hypothesis that ETB 24 receptors contribute to impaired vasodilatory function in postmenopausal women (PMW). We 25 measured flow-mediated dilation (FMD) using ultrasound, and cutaneous nitric oxide-mediated 26 
INTRODUCTION 44
Primary aging is a major risk factor for cardiovascular disease (CVD) (68). One 45 mechanism linking the age-related increase in CVD may be impaired endothelial function or 46 impaired vasodilatory function of the vasculature (32, 59, 66). Although it has been well 47 established that declines in endothelial function occur with healthy aging (6, 15, 45, 52, 56, 65), 48 the age at which endothelial function becomes impaired differs between men and women; 49 endothelial function declines at a faster rate in women after menopause (6). The vascular endothelium releases several vasoactive substances to mediate dilation and 56 constriction. It is well known that impaired nitric oxide (NO) production or availability 57 contributes to endothelial dysfunction. Recently, age-related impairments in endothelial function 58 have also been associated with endothelin-1 (ET-1) in men (10, 65). ET-1 is a potent 59 vasoconstrictor produced and released from endothelial cells that acts on two receptor subtypes, 60 ETA and ETB. Both receptors are located on the vascular smooth muscle and mediate 61 vasoconstriction (3, 17, 34), however ETB receptors are also located on the endothelium and 62 mediate vasodilation (17, 23) . In a recent review article, Kitada et al. suggest that the efficacy of 63 ET-1 receptor antagonists differ between men and women, and sex differences in CVD may be 64 related to ETB receptors (28). ET-1 preferentially binds to ETB receptors in women (12), and 65 prior studies demonstrate sex differences in ET-1 receptor responses (24, 53). Moreover, it haslast menses for PMW was 8±1 years. All women were familiarized with the equipment and 112 experimental protocol before the testing visit. 113
114

Experimental Protocol 115
Women reported to the laboratory (22°C) either in the morning or afternoon after 116 refraining from exercise and alcohol for 24 hours, caffeine for 12 hours, and food for at least 4 117
hours. An over-the-counter urine pregnancy test was performed in young women. Women lay 118 supine for ~20-30 minutes, and a venous blood sample was obtained from an antecubital vein to 119 assess sex steroids and plasma ET-1. Conduit artery endothelial function was assessed in the 120 brachial artery using flow-mediated dilation (FMD) as previously described (11, 37). Briefly, a 121 longitudinal image of the brachial artery was obtained via ultrasound (GE P5; Healthcare, 122 Waukesha, WI). Baseline artery diameters were assessed on a continuous basis for 1 minute, at 123 which time a cuff placed below the antecubital fossa was inflated to supra-systolic pressure 124 (Hokanson Rapid Cuff Inflator; Bellevue, WA) and remained inflated for 5 minutes. Upon cuff 125 deflation, brachial artery diameters were assessed continuously for an additional 2 minutes. 126
Brachial artery diameters were assessed offline on a continuous basis using a custom LabVIEW 127 program; FMD was calculated as a percent change from baseline to peak diameter. 128
Cutaneous microdialysis: Under sterile conditions, 3 microdialysis fibers (CMA 31 129 Linear Microdialysis Probe, Harvard Apparatus, Kista, Sweden) were place in the intradermal 130 space on the dorsal side of the right forearm as previously described (62, 64). Briefly stated, a 131 23-gauge needle was placed in the intradermal space, with an entrance and exit site of 2 cm. 132
Each microdialysis site was separated by at least one inch. The microdialysis fibers were then 133 threaded through the lumen of the needle, and the needle was removed, leaving the microdialysis The vasodilatory response to local heating is bi-phasic, with the initial peak attributed to an axon 148 reflex, followed by a secondary prolonged plateau phase (~25-35 minutes after heating begins) 149 which is predominantly mediated by nitric oxide (4, 26, 41). As such, we used this prolonged 150 plateau phase as our primary indicator of cutaneous vasodilatory responsiveness. After the 151 heating-induced plateau was established and maintained for 5-minutes, 28mM of sodium 152 nitroprusside was perfused (5uL/min) through all microdialysis fibers, and the temperature in the 153 local heating units was increased to 43°C to elicit maximal vasodilation as previously described 154 (62). Blood pressure was measured throughout the protocol using an automated brachial blood 155 pressure machine on the contralateral arm (Dinamap Dash 2000, GE Medical Systems). 156
157
Wenner et al.
R1 -Menopause and Vascular Function 8 Blood Analysis 158
Blood samples for the analysis of serum estradiol (s[E 2 ]) and progesterone (s[P 4 ]) were 159 collected in separate tubes without an anticoagulant. A separate blood sample was collected in an 160
EDTA tube for the analysis of plasma ET-1 (p[ET-1]). All tubes were centrifuged, to separate 161 the serum or plasma, which was then pipetted off and frozen at -80C until time of analysis. 162
Serum [E 2 ] and [P 4 ] were determined using competitive enzyme-linked immunosorbent assays 163 (ELISA, Alpco, Salem, NH). The range for the E 2 assay was 0 -200 pg/ml with a sensitivity of 164 1.399 pg/ml. Intra-assay and interassay coefficients of variation for the E 2 assay were 2.72% and 165 0.17%, respectively. The range for the P 4 assay was 0.3 -60 ng/ml with a sensitivity of 0.1 166 ng/ml. Intra-assay and interassay coefficients of variation for the P4 assay were 3.52% and 167
1.42%, respectively. Plasma ET-1 was analyzed using an ELISA (R&D systems, Minneapolis, 168 MN, USA). Intra-and inter-assay coefficients of variation were less than 2.5%. All samples 169
were measured at a wavelength of 450nm on an Infinite F200 Pro microplate reader and data was 170 analyzed with Magellan IQ software (Tecan Group Ltd., Männedorf, CH). 171
172
Data Analysis and Statistics 173
Cutaneous blood flow was recorded at 1000 Hz using Powerlab and LabChart 174 (ADInstruments, Bella Vista, NSW, Australia). After a stable plateau was achieved in response 175 to local heating, 2-minutes of cutaneous blood flow at each microdialysis site was analyzed. 176
Subsequently, maximal vasodilatory capacity was also measured at each site (2-minutes) after a 177 stable plateau was achieved from the SNP+43°C. Data are presented as cutaneous vascular 178 conductance (CVC; cutaneous blood flow / mean arterial pressure) and normalized to themaximal vasodilatory capacity reached from SNP+43°C (%CVC max ) to account for site-to-site 180 variations in blood flow (62, 64). 181
Subject demographics, serum hormones, and plasma ET-1 were compared between 182 groups using unpaired t-tests. The effect of ET-1 receptor blockade (drug) on vasodilatory 183 responses in YW and PMW (group) were conducted using 3x2 Mixed Design ANOVA. 184
Additionally, MAP and CVC max was compared across protocol periods/microdialysis sites 185 between groups using a 4x2 Mixed Design ANOVA. Model assumptions were tested using 186 were similar in both groups. Plasma ET-1 was higher in PMW (Table 1) 
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As expected, endothelial function as measure by brachial artery FMD was lower in PMW 204 (7.5±0.5 vs. 5.6±0.6%, P<0.05; Figure 1A ). Consistent with these findings, the plateau phase of 205 cutaneous vasodilation in response to local heating was also blunted in PMW (92±2 vs. 83±4%, 206 P<0.05; Figure 1B) . 207
There was a significant drug by group interaction detected for the ET-1 receptor 208
antagonists (P<0.05; Figures 2A & 2B) . In YW, blockade of ETB receptors reduced cutaneous 209 vasodilation (P<0.05; Figure 2A ). However, ETA receptor blockade had no effect on 210 vasodilatory responses in YW (Figure 2A) . In contrast to YW, ETB receptor blockade increased 211 vasodilatory responses to local heating in PMW (P<0.05; Figure 2B ); a similar response in PMW 212 was also observed during ETA receptor blockade (P<0.05; Figure 2B ). Blood pressure was 213 higher in PMW than YW throughout the microdialysis protocol. There was a small but 214 significant reduction in BP in both groups during the heating at 43°C+SNP compared to plateau 215 phase achieved with heating at 42°C ( The main novel finding of the current study is that impaired vasodilation in PMW is due 223 in part to a loss of ETB receptor-mediated vasodilation. In YW, blockade of ETB receptors 224 resulted in a reduction in vasodilation, demonstrating that ETB receptors mediate vasodilation. In The mechanisms contributing to vascular dysfunction in PMW are complex due to the 239 dramatic changes in ovarian hormones concomitant with an aging vascular system. Although 240 there have been significant advances in our understanding of impaired vasodilatory function in 241 women during and after menopause, the underlying mechanisms are not completely understood 242 (18, 43, 44, 46). It has previously been established that aging and estrogen deprivation are 243 associated with a reduction in NO bioavailability (6, 14, 58). Furthermore, this reduction in NO 244 bioavailability is associated with eNOS uncoupling and reactive oxygen species in PMW, and 245 estrogen deficiency plays an obligatory role in this response (46, 47). Thus, it has become 246 increasingly apparent that dysfunction in the production and/or release of NO is a primary 247 mediator of impaired vasodilatory function in PMW. However, impaired NO production andbioavailability may also be related to ET-1 (54, 60), and ET-1 signaling has recently been 249 implicated in the development of endothelial dysfunction in men (10, 65). 250
To our knowledge, our study is the first to examine a role for ET-1 in contributing to 251 impaired vasodilatory function in PMW. Plasma levels of ET-1 generally increase in PMW (36) particularly ETB receptors, in cell and animal models (9, 48, 49). In humans, the proportion of 267 ETA and ETB receptors differs between men and women (12), and alterations in sex steroids 268 may influence ETB receptor control of vascular function (62, 63). As such, we hypothesized that 269 ETB receptor control of vascular function would be altered after menopause. In the current 270 study, we show a differential regulation of cutaneous vasodilatory responses by the ETB receptorin young and PMW: in YW, ETB receptors mediate vasodilation; however, this vasodilatory 272 effect is lost after menopause. We speculate that either endothelial ETB receptors are 273 downregulated or vascular smooth muscle ETB receptors are upregulated after menopause. 274
Because ETB receptors are also within peripheral nerves and mediate vasoconstriction (35), it is 275 possible that greater sympathetic tone in PMW is contributing to our findings of reduced 276 dilation. Although we are not able to discern the precise mechanism or changes in receptor 277 expression from the current study, our data are an important first step in showing functional 278 differences in the regulation of vascular function in humans with age/menopause via the ETB 279 receptor. Importantly, our findings are in contrast to previous findings in men, showing that 280 impaired endothelial function with aging in men occurs in part due to greater ETA receptor 281 mediated vasoconstriction (65). Therefore, sex differences in the ET-1 system may be a primary 282 contributing factor to the known sex differences in endothelial dysfunction and CVD (6, 55, 68). 283
It is not clear if the loss of ET-B mediated dilation in PMW is primarily an aging effect, 284 or due to changes in reproductive hormone status. It is challenging to completely separate the 285 effect from aging from the hormonal changes that occur with menopause. We tested young 286 women during the early follicular phase of menstruation or during the placebo week of oral 287 contraceptive use to minimize the impact of circulating reproductive hormones, consistent with 288 prior studies examining vascular function in women (7, 14, 16, 38). However, the composition of 289 synthetic hormones can cause differential action on endothelial function (38, 40, 57). We were 290 not powered to examine these differences in the current study, but is an interesting area for future 291 investigation given the use of synthetic hormones not only in young women for contraceptive 292 use, but also in postmenopausal women for the treatment of menopausal symptoms.
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Limitations: We recognize that there are other vasoactive substances regulating vascular 294 endothelial function, such as nitric oxide and prostaglandins. Our current analysis was focused 295 on the role of ET-1, and we were not able explore additional mechanisms or interactions with 296 ET-1. However, the findings of our study provide a foundation for future studies to explore 297 additional mechanisms and interactions with ET-1. Second, ET-1 exerts other effects that can 298 contribute to impaired vasodilatory function. For example, ET-1 can stimulate reactive oxygen 299 species (50, 61), and oxidative stress has been shown to contribute to impaired endothelial 300 function in PMW (47). Increased arterial stiffness is also evident in PMW (18, 67); this increased 301 stiffness in PMW was attenuated after infusion of ascorbic acid, indicating a role for oxidative 302 stress (18). In addition, ET-1 can also activate matrix metalloproteinases and increase collagen 303 production, cause smooth muscle proliferation, induce fibrosis, and lead to inflammation (2, 30, 304 51). Therefore, ET-1 may be involved in the greater arterial stiffness observed in PMW. 305
Unfortunately, we did not measure arterial stiffness in the current investigation so cannot 306 determine whether there was a relationship between ET-1 receptor function and arterial stiffness. 307
Taken together, the interactions of multiple regulatory pathways are likely involved in the 308 impaired vascular function that occurs after menopause. 309
In conclusion, we demonstrate that the ET-1 system plays an important role in the 310 impaired vascular function observed in PMW. Specifically, we show that ETB receptor mediated 311 dilation in young women is lost after menopause. These data add to our understanding of the 312 mechanisms that contribute to impaired vasodilatory function that occurs after menopause. 313
314
Perspectives 315
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It is now well recognized that sex difference are apparent in the prevalence of CVD with 316 aging, such that CVD is more prevalent in women after menopause. 
